Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 13/20 | 0.56 |
| ▸ | NPY5R | Q15761 | 9/20 | 0.56 |
| ▸ | NPY1R | P25929 | 9/20 | 0.56 |
| ▸ | NPY2R | P49146 | 6/20 | 0.56 |
| ▸ | TFPI | P10646 | 1/20 | 0.54 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.54 |
| ▸ | VIPR2 | P41587 | 3/20 | 0.53 |
| ▸ | VIPR1 | P32241 | 1/20 | 0.53 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16507943 | 0.97 | TFPI (0.57) | NPY4RNPY5RNPY1RNPY2RTFPI | |
| SCHEMBL16507918 | 0.94 | NPY4R (0.61) | NPY4RNPY5RNPY1RNPY2RTFPI | |
| SCHEMBL16507968 | 0.93 | NPY4R (0.60) | NPY4RNPY5RNPY1RNPY2RTFPI | |
| SCHEMBL16508147 | 0.92 | TFPI (0.61) | NPY4RNPY5RNPY1RNPY2RTFPI | |
| SCHEMBL16507944 | 0.91 | NPY5R (0.62) | NPY4RNPY5RNPY1RNPY2RTFPI | |
| SCHEMBL16507938 | 0.91 | NPY5R (0.62) | NPY4RNPY5RNPY1RNPY2RTFPI | |
| SCHEMBL16508074 | 0.90 | IL23R (0.55) | NPY4RNPY5RNPY1RNPY2RTFPI | |
| SCHEMBL16508093 | 0.90 | TFPI (0.63) | NPY4RNPY5RNPY1RNPY2RTFPI | |
| SCHEMBL16508047 | 0.89 | KEAP1 (0.65) | NPY4RNPY5RNPY1RNPY2RTFPI | |
| SCHEMBL16508111 | 0.89 | TFPI (0.62) | NPY4RNPY5RNPY1RNPY2RTFPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110294738-A1 | PTHR1 RECEPTOR COMPOUNDS | ANTHOR THERAPEUTICS, INC. | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294738-A1 | PTHR1 RECEPTOR COMPOUNDS | PTH1R, MC1R, CASR | NPY4R 1387/4885NPY5R 1478/4885NPY1R 800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.